Vibativ effectively helped treat secondary bacterial infections in COVID-19 patients
On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin)…
-
-
Data published in NEJM showed Pfizer’s Tofacitinib met primary endpoint in Brazilian study in patients with COVID-19 pneumonia
On Jun. 16, 2021, Pfizer and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced…
-
Quidel received amended Emergency Use Authorization for new Sofia Q rapid antigen test device
On Jun. 11, 2021, Quidel announced today that it had received an amended Emergency Use Authorization (EUA) from…
-
FDA approved PREVNAR 20, Pfizer’s pneumococcal 20-valent conjugate vaccine for adults ages 18 years or older
On Jun. 8, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved PREVNAR 20…
-
Merck announced positive topline results from phase 3 pediatric studies for investigational 15-valent pneumococcal conjugate vaccine
On May 20, 2021, Merck announced V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity…
-
Trevena announced TRV027 selected for study in global REMAP-CAP trial in COVID-19 patients
On Apr. 21, 2021,Trevena announced that TRV027, the Companyﾒs novel AT1 receptor selective agonist, had been selected for…
-
EMA accepted Pfizerﾒs MAA for investigational 20-valent pneumococcal conjugate vaccine
On Feb. 26, 2021, Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization…
-
Study demonstrated macrolide-resistance in S pneumoniae in the US exceeded 25 percent threshold set in CABP guidelines
On Feb. 23, 2021, Nabriva Therapeutics announced publication of a study documenting the high rates of macrolide-resistant Streptococcus…
-
NIAID microbiota study iIdentified nutrient that help prevent bacterial infection
On Jan. 15, 2021, scientists studying the bodyﾒs natural defenses against bacterial infection announced they had identified a…
-
RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
-
FDA accepted for priority review the BLA for Pfizerﾒs investigational 20-valent pneumococcal conjugate vaccine
On Dec. 8, 2020, Pfizer announced that the FDA accepted for priority review a Biologics License Application (BLA)…
-
RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
-
RedHill completed enrollment for COVID-19 US phase 2 study with opaganib
On Nov. 16, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
-
Novartis’ randomized, double-blind, placebo-controlled CAN-COVID trial failed to meet endpoints
On Nov. 5, 2020, Novartis announced data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial…
-
Merck announced positive topline results from phase 3 adult studies evaluating V114 15-valent pneumococcal conjugate vaccine
On Oct. 20, 2020, Merck announced findings from two additional Phase 3 studies evaluating the safety, tolerability and…
-
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
-
Gilead Sciences signed joint procurement agreement with European Commission for Veklury (remdesivir)
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
-
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
-
Brazil approved RedHill Biopharma’s phase 2/3 COVID-19 study with opaganib
On Sept. 22, 2020, RedHill Biopharma announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing…
-
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
On Sept. 17, 2020, Genentech, a member of the Roche Group announced that the Phase III EMPACTA study…
-
UTHealth joined NIH trial to test antibodies and other experimental outpatient treatments for COVID-19 pneumonia
On Sept. 15, 2020, the University of Texas Health Science Center at Houston (UTHealth) announced that a study…
-
Text analysis software track global biothreats, such as COVID-19
On Sept. 14, 2020, at the Pacific Northwest National Laboratory (PNNL) reported that U.S. analysts monitoring global biothreats…
-
Merck announced positive topline results from phase 3 adult studies evaluating investigational 15-valent pneumococcal conjugate vaccine
On Sept. 9, 2020, Merck announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity of…
-
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
-
RedHill Biopharma’s Opaganib awarded COVID-19 grant by State of Pennsylvania
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
-
RedHill Biopharma Announced Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in…
-
Largest global study on hydroxychloroquine safety finds increased cardiovascular risk with azithromycin
On Aug. 24, 2020, the combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including…
-
Vanda Pharma’s interim analysis from ODYSSEY study showed tradipitant may accelerate clinical improvement in patients with COVID-19 pneumonia
On Aug. 18, 2020, Vanda Pharma reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2…
-
Experimental COVID-19 vaccine prevented severe disease in mice
On Aug. 11, 2020, an experimental vaccine was reported to be effective at preventing pneumonia in mice infected…
-
RedHill Biopharma initiated global phase 2/3 study for COVID-19
On Jul. 30, 2020, RedHill Biopharma announced that it has initiated a global Phase 2/3 clinical study evaluating…
